Medical Gas Regulation Review; Announcement of Public Meeting; Correction, 70248 [2013-28083]

Download as PDF 70248 Federal Register / Vol. 78, No. 227 / Monday, November 25, 2013 / Proposed Rules includes the month we make the first recurring monthly SSI benefit payment to you following your period of suspension or termination and subsequent reinstatement of those benefits. ■ 10. Revise § 416.1920 to read as follows: § 416.1920 subpart. Your appeal rights under this (a) Your appeal rights to the State. You have the right to appeal to the State if you disagree with any of the State’s actions regarding reimbursement of the interim assistance. You are not entitled to a Federal hearing to appeal the State’s actions regarding reimbursement for interim assistance. (b) Your appeal rights to us. You have the right to appeal to us, in accordance with subpart N of this part— (1) The amount of your retroactive SSI benefit payments we withheld from you; (2) The amount of your retroactive SSI benefit payments we sent to the State to reimburse the State for interim assistance it paid to you; and (3) The amount of your retroactive SSI benefit payments due to you after we reimbursed the State for interim assistance it paid to you. § 416.1922 [Removed and Reserved] 11. § 416.1922 is removed and reserved. ■ Programs, Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD 20993–0002, 301–796–3519, FAX: 301–847–8753, email: Mary.Gross@fda.hhs.gov; or Christine Kirk, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD 20993–0002, 301–796–2465, FAX: 301– 847–8440, email: Christine.Kirk@fda.hhs.gov; or Urvi Desai, Center for Veterinary Medicine, Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, email: Urvi.Desai@fda.hhs.gov. SUPPLEMENTARY INFORMATION: In the Federal Register of Friday, November 1, 2013, in FR Doc. 2013–26056, on page 65588 the following corrections are made: 1. In the third column, in the last sentence of the second paragraph under Registration and Requests for Oral Presentations, ‘‘http://www.fda.gov/ Drugs/NewEvents/ucm370351.htm’’ is corrected to read ‘‘http://www.fda.gov/ Drugs/NewsEvents/ucm370351.htm’’. 2. In the third column, in the first sentence of the third paragraph under Registration and Requests for Oral Presentations, ‘‘http://www.fda.gov/ Drugs/NewEvents/ucm370351.htm’’ is corrected to read ‘‘http://www.fda.gov/ Drugs/NewsEvents/ucm370351.htm’’. Dated: November 19, 2013. Leslie Kux, Assistant Commissioner for Policy. [FR Doc. 2013–28034 Filed 11–22–13; 8:45 am] BILLING CODE 4191–02–P [FR Doc. 2013–28083 Filed 11–22–13; 8:45 am] DEPARTMENT OF HEALTH AND HUMAN SERVICES BILLING CODE 4160–01–P Food and Drug Administration 21 CFR Chapter I ENVIRONMENTAL PROTECTION AGENCY [Docket No. FDA–2013–N–0001] 40 CFR Parts 52 and 69 Medical Gas Regulation Review; Announcement of Public Meeting; Correction [EPA–R09–OAR–2013–0697; FRL–9902–75– Region 9] AGENCY: Food and Drug Administration, HHS. Notice of public meeting; correction. ACTION: The Food and Drug Administration is correcting a document that appeared in the Federal Register of November 1, 2013 (78 FR 65588). The document announced a public meeting entitled ‘‘Medical Gas Regulation Review.’’ The document was published with an incorrect Web site. This document corrects that error. DATES: Effective November 25, 2013. FOR FURTHER INFORMATION CONTACT: Mary Gross, Office of Executive emcdonald on DSK67QTVN1PROD with PROPOSALS SUMMARY: VerDate Mar<15>2010 17:24 Nov 22, 2013 Jkt 232001 Approval and Promulgation of Implementation Plans; Commonwealth of the Northern Mariana Islands; Prevention of Significant Deterioration; Special Exemptions From Requirements of the Clean Air Act Environmental Protection Agency (EPA). ACTION: Proposed rule. AGENCY: Under the Clean Air Act, EPA is proposing to disapprove the state implementation plan (SIP) for the Commonwealth of the Northern Mariana Islands (CNMI) with respect to prevention of significant deterioration (PSD), and to incorporate by reference the Federal PSD regulations into the SUMMARY: PO 00000 Frm 00009 Fmt 4702 Sfmt 4702 applicable CNMI plan. EPA is also proposing to approve a petition by CNMI for an exemption of the applicable PSD major source baseline date and trigger date under Federal PSD regulations, and to establish an alternate date, January 13, 1997, as the major source baseline date and trigger date in CNMI. EPA is also proposing to make certain corrections that were made in previous rulemakings. This action would establish the Federal PSD regulations as a basic element of the CNMI implementation plan and, through the exemption, would establish January 13, 1997 as the major source baseline date (and trigger date) under the PSD program in CNMI for sulfur dioxide, PM10 and nitrogen dioxide. DATES: Comments must be received on or before December 26, 2013. Request for a public hearing must be received by December 10, 2013. If we receive a request for a public hearing, we will publish information related to the timing and location of the hearing and the timing of a new deadline for public comments. ADDRESSES: Submit comments, identified by docket number EPA–R09– OAR–2013–0697, by one of the following methods: • Federal eRulemaking Portal: www.regulations.gov. Follow the on-line instructions. • E-Mail: rios.gerardo@epa.gov. • Mail or Deliver: Gerardo Rios (AIR–3), U.S. Environmental Protection Agency Region IX, 75 Hawthorne Street, San Francisco, CA 94105. Instructions: All comments will be included in the public docket without change and may be made available online at www.regulations.gov, including any personal information provided, unless the comment includes Confidential Business Information (CBI) or other information whose disclosure is restricted by statute. Information that you consider CBI or otherwise protected should be clearly identified as such and should not be submitted through www.regulations.gov or email. The www.regulations.gov portal is an ‘‘anonymous access’’ system, and EPA will not know your identity or contact information unless you provide it in the body of your comment. If you send email directly to EPA, your email address will be automatically captured and included as part of the public comment. If EPA cannot read your comment due to technical difficulties and cannot contact you for clarification, EPA may not be able to consider your comment. Docket: The index to the docket for this action is available electronically at E:\FR\FM\25NOP1.SGM 25NOP1

Agencies

[Federal Register Volume 78, Number 227 (Monday, November 25, 2013)]
[Proposed Rules]
[Page 70248]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-28083]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Chapter I

[Docket No. FDA-2013-N-0001]


Medical Gas Regulation Review; Announcement of Public Meeting; 
Correction

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of public meeting; correction.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration is correcting a document that 
appeared in the Federal Register of November 1, 2013 (78 FR 65588). The 
document announced a public meeting entitled ``Medical Gas Regulation 
Review.'' The document was published with an incorrect Web site. This 
document corrects that error.

DATES: Effective November 25, 2013.

FOR FURTHER INFORMATION CONTACT: Mary Gross, Office of Executive 
Programs, Food and Drug Administration, 10903 New Hampshire Ave., 
Silver Spring, MD 20993-0002, 301-796-3519, FAX: 301-847-8753, email: 
Mary.Gross@fda.hhs.gov; or Christine Kirk, Center for Drug Evaluation 
and Research, Food and Drug Administration, 10903 New Hampshire Ave., 
Silver Spring, MD 20993-0002, 301-796-2465, FAX: 301-847-8440, email: 
Christine.Kirk@fda.hhs.gov; or Urvi Desai, Center for Veterinary 
Medicine, Food and Drug Administration, 7500 Standish Pl., Rockville, 
MD 20855, email: Urvi.Desai@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: In the Federal Register of Friday, November 
1, 2013, in FR Doc. 2013-26056, on page 65588 the following corrections 
are made:
    1. In the third column, in the last sentence of the second 
paragraph under Registration and Requests for Oral Presentations, 
``http://www.fda.gov/Drugs/NewEvents/ucm370351.htm'' is corrected to 
read ``http://www.fda.gov/Drugs/NewsEvents/ucm370351.htm''.
    2. In the third column, in the first sentence of the third 
paragraph under Registration and Requests for Oral Presentations, 
``http://www.fda.gov/Drugs/NewEvents/ucm370351.htm'' is corrected to 
read ``http://www.fda.gov/Drugs/NewsEvents/ucm370351.htm''.

    Dated: November 19, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2013-28083 Filed 11-22-13; 8:45 am]
BILLING CODE 4160-01-P